menu

Loading...

CLGN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

0.595

Open

0.540

VWAP

0.56

Vol

13.09K

Mkt Cap

7.27M

Low

0.503

Amount

7.28K

EV/EBITDA(TTM)

--

Total Shares

12.78M

EV

-1.28M

EV/OCF(TTM)

--

P/S(TTM)

2.73

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

Show More

Events Timeline

(ET)

2026-02-26

08:20:00

CollPlant Secures Korean Patent for Photocurable Dermal Filler Technology

2026-02-05 (ET)

2026-02-05

08:10:00

CollPlant Biotechnologies Issues 1.6M Shares at $1.25 Each

2026-01-09 (ET)

2026-01-09

16:20:00

CollPlant Files $100M Mixed Securities Shelf

2025-11-26 (ET)

2025-11-26

07:35:33

CollPlant to Cut Workforce by 25%

2025-11-26

07:32:38

CollPlant announces Q3 non-GAAP EPS of 25 cents, compared to a loss of 33 cents in the previous year.

2025-10-27 (ET)

2025-10-27

07:11:14

CollPlant enhances rhCollagen offerings in the U.S. and Canada

2025-10-20 (ET)

2025-10-20

07:03:00

CollPlant's Collink.3D Outperforms Matrigel in Recent Study

2025-09-30 (ET)

2025-09-30

07:05:06

CollPlant's dermal filler demonstrates encouraging non-clinical outcomes

2025-09-15 (ET)

2025-09-15

07:07:36

CollPlant broadens availability of Vergenix STR product across Europe

News

PRnewswire

02-23PRnewswire

CollPlant Launches BioFlex Bioink Kit for 3D Bioprinting

Newsfilter

02-23Newsfilter

CollPlant Launches BioFlex Bioink for Advanced 3D Bioprinting

Benzinga

Wall Street Analysts Adjust Ratings on Top Stocks

NASDAQ.COM

2025-11-29NASDAQ.COM

D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)

Benzinga

2025-11-28Benzinga

D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact

Newsfilter

2025-11-26Newsfilter

CollPlant Partners with U.S. Logistics Center to Expand North American Market

Valuation Metrics

The current forward P/E ratio for Collplant Biotechnologies Ltd (CLGN.O) is -13.45, compared to its 5-year average forward P/E of 7.04. For a more detailed relative valuation and DCF analysis to assess Collplant Biotechnologies Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

7.04

Current PE

-13.45

Overvalued PE

39.43

Undervalued PE

-25.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

57.16

Current PS

1.25

Overvalued PS

171.77

Undervalued PS

-57.45

Financials

AI Analysis

Annual

Quarterly

Whales Holding CLGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Collplant Biotechnologies Ltd (CLGN) stock price today?

The current price of CLGN is 0.569 USD — it has increased 4.4

What is Collplant Biotechnologies Ltd (CLGN)'s business?

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

What is the price predicton of CLGN Stock?

Wall Street analysts forecast CLGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Collplant Biotechnologies Ltd (CLGN)'s revenue for the last quarter?

Collplant Biotechnologies Ltd revenue for the last quarter amounts to 77.00K USD, increased 1825.00

What is Collplant Biotechnologies Ltd (CLGN)'s earnings per share (EPS) for the last quarter?

Collplant Biotechnologies Ltd. EPS for the last quarter amounts to -0.27 USD, decreased -28.95

How many employees does Collplant Biotechnologies Ltd (CLGN). have?

Collplant Biotechnologies Ltd (CLGN) has 57 emplpoyees as of March 04 2026.

What is Collplant Biotechnologies Ltd (CLGN) market cap?

Today CLGN has the market capitalization of 7.27M USD.